To view more news and media here in our Newsroom

Click Here

Georgetown-Led Study Leads to First FDA-Approved Drug in Decades to Improve Survival in Small Cell Lung Cancer

The U.S. Food and Drug Administration’s approval today of atezolizumab (Tecentriqâ, Genentech) in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer (SCLC) marks the end of numerous failed attempts to improve survival for people with the deadly disease. “This is monumental for lung cancer patients,” says Stephen Liu, MD, an oncologist at MedStar Georgetown University Hospital who specializes in treating lung cancer and co-led the clinical trial leading to today’s approval through the Georgetown Lombardi Comprehensive Cancer Center. “Atezolizumab allowed us to achieve what for we thought for decades was beyond reach: an improvement in…

Read More

Researchers Decode How Cancer Drug Works in Brains of Parkinson’s Disease Patients

WASHINGTON  — Laboratory analysis from the first arm of a phase II clinical trial testing the use of nilotinib in patients with Parkinson’s disease demonstrates precisely how the agent increases levels of dopamine in the brains of study participants, says a research team at Georgetown University Medical Center. Symptoms of Parkinson’s, such as motor dysfunction, are a result of a dopamine loss. In the journal Pharmacology Research & Perspectives, investigators report that a single low dose of the leukemia drug, nilotinib (Tasigna® by Novartis), reduces levels of a toxic protein that prevents the brain from utilizing dopamine that is stored…

Read More

First Patient in a Clinical Trial Using Her Own Immune System to Personalize Treatment for Non-Hodgkin Lymphoma Still Experiencing Remission Six Months Later

WASHINGTON – The first cancer patient to be treated as part of a CAR-T cell clinical trial at MedStar Georgetown University Hospital through Georgetown Lombardi Comprehensive Cancer Center is still in “complete remission” six months after receiving the treatment. Daisy Diggs Daisy Diggs, 67, of Laurel, Maryland volunteered for the experimental treatment after a lengthy battle with stage-three non-Hodgkin lymphoma, a type of blood cancer. Following her diagnosis in 2015, the mother of two and grandmother of four developed several tumors that could not be eliminated with chemotherapy alone. “I had tumors in my lymph nodes, hip, pelvis, neck and…

Read More

Large Study Reveals Long-Term Outcomes for Prostate Cancer Patients Treated with High Dose, Short Term Radiation like CyberKnife Radiotherapy

WASHINGTON –– A large, national study examining a radiation treatment for prostate cancer––popular because it delivers a high dose of therapy in a very short time frame––supports its routine use.  The study, conducted at cancer centers around the United States including at Georgetown Lombardi Comprehensive Cancer Center, looks at long term follow up data for stereotactic body radiotherapy (SBRT) used to treat more than 2,100 men with prostate cancer that had a low or intermediate risk of recurring. The results were published Feb. 8 in the journal JAMA Network Open. At MedStar Georgetown University Hospital, the therapy is delivered by a…

Read More

Top News
Georgetown-Led Study Leads to First FDA-Approved Drug in Decades to Improve Survival in Small Cell Lung Cancer
News
Georgetown-Led Study Leads to First FDA-Approved Drug in Decades…
Close
What can we
Help you Find?

Begin your search for a physician, service or location.

Find a Doctor

Start looking for the right physician to meet your health needs.

Find a Doctor

Important Parking Information

Parking for patients and visitors has changed! Click here for details.

Parking Info

Contact Us

For access to unsurpassed health care treatment, contact us now.

Contact Us